Research Reveals Global Growth of Secure DevOps
New research from Secure Code Warrior ®, the global secure coding company, has revealed an attitudinal shift in the software development industry, with organisations bucking traditional practices for DevOps and Secure DevOps.
The global survey of professional developers and their managers found seven in 10 organisations (70%) recognise the importance of secure coding practices, with results indicating an industry-wide shift from reaction to prevention is underway.
Dr. Matias Madou, Chief Technology Officer and Co-Founder at Secure Code Warrior, said, “We are seeing a fundamental shift in mindsets across the world, as the industry slowly moves from reactive, band-aid solutions rolled out after a breach, to the proactive and human-led practice of writing quality software that is intrinsically free from vulnerabilities right from the very first keystroke.”
“This research shows that ‘secure code’ is becoming synonymous with ‘quality code’ within software development, and security is becoming the responsibility of development teams and leaders—not just AppSec professionals,” he said.
Secure coding seen as ‘reactive’
Reactive practices like using tools on deployed applications and manually reviewing code for vulnerabilities were the top two practices respondents associated with coding securely. However, a proactive shift in mindset was evidenced across the globe, with more than half (55%) of the developers surveyed also recognising secure coding as the active, ongoing practice of writing software protected from vulnerabilities.
Managers and developers are misaligned
Over half (55%) of managers surveyed said secure coding was practised and integrated throughout the entire development process, compared to only 43% of developers. Conversely, 36% of developers consider secure coding during development but not the design phase, as opposed to under one-third (32%) of managers.
Secure code an increasing indicator of success
While those surveyed identified ‘application performance’ and ‘functionality and features’ as the most common success metrics within software development (67% and 62% respectively), almost four in five (79%) respondents said the importance of ‘secure code’ was growing in prominence.
Application security is shifting
Almost half of respondents (46%) said development leads and teams should be responsible for application security rather than AppSec teams (24%). Over eight in 10 (81%) developers surveyed said they were accountable for any vulnerable code produced.
Developers motivated to upskill
‘Increased productivity and efficiency’, ‘curiosity’ and ‘avoiding problems caused by insecure code’ were identified as the leading intrinsic motivators to learn secure coding (20%, 14% and 11% respectively). Despite only 10% of respondents listing career advancement as a personal motivator, four in five (81%) managers were more likely to hire talent with secure coding skills.
More training is needed
91% of managers surveyed said they faced greater than average difficulty when implementing secure coding practices within their organisation, despite the overwhelming majority of respondents (97%) believing they were sufficiently trained. Perhaps, this is because almost nine in 10 (88%) developers surveyed said coding securely was challenging.
Madou added, “With OWASP’s Top 10 software vulnerabilities causing more security breaches over the past two decades than any others, now is the time for businesses to upskill developers to gain the knowledge and skills needed to stamp out insecure code and prevent issues from occurring in the first place.”
“Code is at the heart of everyday interactions, and Secure Code Warrior is focused on championing security-skilled developers who can create amazing, safe software for our connected world.”
To gain early access to the report, ‘Shifting from reaction to prevention: The changing face of application security 2021’, register your interest at scw.buzz/earlyaccess
Methodology
Secure Code Warrior® commissioned Evans Data Corporation, the market intelligence leader within the IT industry, to conduct a global survey of developers and decision-makers actively engaged in software development. In August 2020, 400 respondents were surveyed across North America, India, the United Kingdom, Europe, Australia, New Zealand and South-East Asia.
About Secure Code Warrior
Secure Code Warrior is the developer-chosen solution for growing powerful secure coding skills. By making secure coding a positive and engaging experience for developers as they increase their software security skills, our human-led approach uncovers the secure developer inside every coder, helping development teams ship quality code faster.
Through inspiring a global community of security-conscious developers to embrace a preventative secure coding approach, our mission is to pioneer a people-first solution to security upskilling, stamping out poor coding patterns for good. Learn more at securecodewarrior.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323006113/en/
Contact information
For media enquiries, to access the full report or arrange an interview:
Carly Ryan, Hotwire
E: securecodewarrior@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
